Author Affiliations: Division of Pulmonary, Allergy and Critical Care and Center for Clinical Epidemiology and Biostatistics, School of Medicine, and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia (Dr Kahn); and Division of General Internal Medicine and Center of Excellence for Patient Safety Research and Practice, Brigham and Women's Hospital and Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts (Dr Bates).
In recent years there have been unprecedented advances in the understanding of the epidemiology, pathophysiology, and treatment of sepsis syndrome.1- 3 This work has culminated in several clinical trials demonstrating the efficacy of targeted interventions to improve sepsis-related outcomes.4- 6 These interventions include not only novel therapeutic agents such as drotrecogin alfa but also treatments directed at improving the way more traditional therapy is delivered, such as early resuscitation and low-tidal volume ventilation for acute lung injury.4- 6
Kahn JM, Bates DW. Improving Sepsis CareThe Road Ahead. JAMA. 2008;299(19):2322-2323. doi:10.1001/jama.299.19.2322